Business Context and Reporting Period
This Form 8-K Current Report was filed by Akebia Therapeutics, Inc. on June 30, 2022. The filing details the entry into and termination of material definitive agreements with Otsuka Pharmaceutical Co. Ltd. regarding the collaboration on the drug vadadustat.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The primary financial impact disclosed is a one-time settlement payment.
- Settlement Payment: Otsuka agreed to pay Akebia a nonrefundable, non-creditable payment of $55,000,000.
- Contingent Payments: Otsuka may pay additional amounts if regulatory fees (for Marketing Authorization Applications or NICE Health Technology Assessments) are refunded to Otsuka and subsequently required to be paid by Akebia upon transfer of responsibilities.
- Waived Rights: Both parties waived rights to future milestone payments, royalties, and cost-sharing under the terminated agreements.
Material Changes Versus Prior Period
The most significant change is the termination of the Collaboration and License Agreements (dated April 25, 2017, and December 18, 2016) between Akebia and Otsuka, effective June 30, 2022. This follows a termination notice previously issued by Otsuka on May 13, 2022. The termination results in the release of all disputes and claims between the parties and the cessation of shared revenue or cost obligations under the original contracts.
Outlook, Management Commentary, and Risks
Regulatory Transfers: Otsuka remains the sponsor for vadadustat Marketing Authorization Applications (MAAs) in the EU, UK, Switzerland, and Australia until transfer to Akebia is approved. Akebia retains final decision-making authority on regulatory submission content. If transfers are not approved within specified timeframes, Otsuka retains the right to withdraw the MAAs.
Clinical Activities: Both parties will complete agreed-upon activities for the Phase 3b MODIFY Study at their own respective costs. Otsuka will also handle packaging validation for European supply at its sole expense.
Health Technology Assessment (HTA): Otsuka has requested a deferral of the NICE HTA process for at least 12 months to allow for the transfer of responsibility to Akebia. If deferral is not granted, Otsuka may withdraw from the process.
Risks: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risks identified in the Company's Form 10-Q for the quarter ended March 31, 2022.
Investor Verification Checklist
- Confirm the receipt and timing of the $55,000,000 settlement payment in upcoming financial reports.
- Monitor the status of MAA transfer requests with the EMA and other relevant authorities for the EU, UK, Switzerland, and Australia.
- Verify the outcome of the NICE HTA deferral request and any potential withdrawal by Otsuka.
- Review the full text of the Termination and Settlement Agreement (to be filed as an exhibit) for specific covenants and exceptions.
- Assess the impact of the termination on Akebia's future revenue projections and cash burn rate given the loss of cost-sharing and royalty streams.